ライフサイエンスコーパス: 123I

1 123I crosstalk into the 99mTc window was 2.79% and was r

2 123I-Ang II formation (as measured by fractional convers

3 123I-Ang metabolites were separated by high-pressure liq

4 123I-FP-CIT-SPECT images were semiquantified using DaTQU

5 123I-Ioflupane single-photon emission computed tomograph

6 123I-ioflupane SPECT, MRI and neuropsychological testing

7 123I-Labeled iodoazomycin arabinoside (IAZA) is a marker

8 123I-labeled iodophenylpentadecanoic acid (IPPA) is a sy

9 123I-labeled T84.66 minibodies demonstrated rapid, high

10 [123I] beta-CIT and single photon emission computed tomog

11 [123I]5-iodo-3-[2(S)-2-azetidinylmethoxy]pyridine (5-I-A-

12 sence of systolic thickening (-3.2% +/- 1%), 123I-IPPA defect magnitude (LAD/left circumflex artery [

13 sults of technetium 99m (99mTc)-,iodine 123 (123I)-, and iodine 131 (131I)-labeled anti-CEA antibodie

14 ssing hNIS could be imaged using iodine-123 (123I) and shown to retain iodide for up to 48 hours.

15 y serial gamma-camera imaging of iodine-123 (123I) uptake both in MV-sensitive KAS-6/1 myeloma xenogr

16 tron emission tomography (PET), iodine-123- (123I) and iodine-131 (131I) -metaiodobenzylguanidine (MI

17 Uptake of radiolabeled (131I [n=2], 123I [n=1], or 111In [n=10]) antibody to MHC-II increase

18 ers labeled with 2beta-carbomethoxy-3beta-(4-123I-iodophenyl)tropane (123I-beta-CIT); nine healthy hu

19 The SPECT radioligand, 3-quinuclidinyl-4-[123I]iodobenzilate ([123I]IQNB), binds to muscarinic rec

20 erebral injection of the thymidine analog 5-[123I]iodo-2'-deoxyuridine ([123I]IUdR).

21 for cortex, regional brain levels of (-)-5-[123I]IBVM ((-)-[123I]5) at 4 h exhibited a linear correl

22 h 12.44% for the uncorrected image and 3.70% 123I crosstalk in the 99mTc image.

23 nAChR agonist radiotracer [123I]5-IA-85380 ([123I]5-IA), we imaged beta2*-nAChR availability in human

24 n brain-slice phantom was filled with 99mTc, 123I or a 3:1 mixture of the two isotopes.

25 everal radionuclides of interest: 90Y, 99mTc,123I and 131I.

26 activity quantitation in simultaneous 99mTc/123I SPECT.

27 ts to clinicians that a positive (abnormal) [123I]FP-CIT SPECT scan, even in a patient with an EPMS,

28 trial was to assess the use of a fatty acid, 123I-iodophenylpentadecanoic acid (IPPA), to identify vi

29 High specific activity [123I]ZIET was synthesized in 33% radiochemical yield (de

30 In addition, [123I]IUdR has a potential role in the scintigraphic dete

31 We studied the feasibility of administering [123I]IBZM as a bolus plus continuous infusion over 8 hr

32 After locoregional administration, [123I]IUdR and [125I]IUdR localize within tumor, clear ra

33 data, were obtained for each volunteer after 123I-IAZA administration.

34 erformed at either 0-7 hr or 18-24 hr after [123I]beta-CIT injection permits calculation of reliable

35 abeled tracer and neurotransmission using an 123I-labeled tracer.

36 lular range Auger electron emitters 125I and 123I, the thymidine analogue 5-iodo-2'deoxyuridine (IUdR

37 ng using two separate line sources (57Co and 123I); and a set of eight patients with Parkinson's dise

38 iquid chromatography, and 123I-Ang-(1-7) and 123I-Ang II were quantified across the myocardial circul

39 Twenty-four 99mTc and 123I activity distributions were simulated on the basis

40 mal and pathologic studies of both 99mTc and 123I activity estimates were very close with ANN to thos

41 ensitive cells in the GI tract for 99mTc and 123I are tenfold lower; those for 131I are fivefold lowe

42 or the simultaneous acquisition of 99mTc and 123I radiotracer distributions in the brain has been dev

43 or the simultaneous acquisition of 99mTc and 123I SPECT images of the brain.

44 arison, unscattered (U) photons of 99mTc and 123I were recorded.

45 by high-pressure liquid chromatography, and 123I-Ang-(1-7) and 123I-Ang II were quantified across th

46 5 dogs underwent LAD occlusion for 3 h, and 123I-IPPA was injected 60 min after reperfusion.

47 Our protocols for imaging both 131I-MIBG and 123I-MIBG, along with the normal distribution of these c

48 istered 99mTc-based radiopharmaceuticals and 123I-Nal, the interval required for urinary levels of ac

49 in brain imaging (11C, 15O, 18F, 99(m)Tc and 123I) and for three radionuclides showing selective upta

50 essed by CEA concentration, 125I-uptake, and 123I-imaging studies.

51 Both [123I]-FPCIT and [123I]-beta-CIT demonstrated decreased striatal uptake in

52 Therefore, fasting is not necessary before 123I-IPPA SPECT imaging for the assessment of myocardial

53 ding of the D2 radioligand [123I]benzamide ([123I]IBZM) was studied with single photon emission compu

54 [(1-ethyl-2-pyrrolidinyl) methyl]benzamide ([123I]IBZM).

55 Both [123I]-FPCIT and [123I]-beta-CIT demonstrated decreased s

56 y using [123I]IUdR and currently using both [123I]IUdR and [125I]IUdR.

57 61.0 +/- 13.2 yr; H&Y Stage I-II) with both [123I] beta CIT-FP and [18F]FDOPA.

58 verestimates in healthy control subjects by [123I]-FPCIT.

59 time activity curves was used to calculate [123I]-iodobenzovesamicol to vesicular acetylcholine tran

60 purpose of the present study was to compare [123I]-beta-CIT with [123I]-FPCIT in a within-subject des

61 We compared [123I] beta CIT-FP/SPECT and [18F]FDOPA/PET in the assess

62 aseline levels over the 5.5 hr of continued [123I]IBZM administration.

63 SPECT imaging during continuous [123I]IBZM infusion provides a powerful within-scan metho

64 In contrast, 123I-IPPA given early after reperfusion following prolon

65 t, in randomized order and on separate days, 123I-IPPA SPECT myocardial imaging under fasting and non

66 midine analog 5-[123I]iodo-2'-deoxyuridine ([123I]IUdR).

67 The diagnostic yield of planar diagnostic 123I scintigraphy at 24 h was superior to that at 5 h fo

68 and 12 healthy volunteers underwent dynamic [123I]-iodobenzovesamicol SPECT and magnetic resonance (M

69 ectron emitters has antineoplastic effects ([123I]IUdR and [125I]IUdR) in addition to its scintigraph

70 5 min with several concentrations of either [123I]IUdR or [125I]IUdR and their colony survival was me

71 eceived transmission 57Co scans and emission 123I scans after injection of 123I-beta-CIT.

72 radiolabeled with the Auger electron emitter 123I or 125I (*IUdR).

73 When labeled with the Auger electron emitter 123I or 125I, IUdR demonstrates therapeutic efficacy.

74 adiolabeled with the Auger electron emitters 123I and 125I in several animal tumor models.

75 Contamination caused by high-energy 123I decay photons was incorporated.

76 We evaluated [123I]-2 beta-carbomethoxy- 3 beta-(4-fluorophenyl)-N-(1-

77 The final 123I-IPPA activity ratio was significantly greater than

78 For 123I, AW + OSEM yielded a bias of 7% in the cerebellum,

79 rding to patient/body region was 80%/65% for 123I-MIBG and 88%/70% for [18F]FDA-PET.

80 The radiation dose biodistribution for 123I-IAZA was studied to assess and characterize its sui

81 asymmetric with a lower bound at 159 keV for 123I.

82 nvert 57Co attenuation values into those for 123I, based on a pixel-by-pixel comparison of two coregi

83 For [123I]-beta-CIT, the mean Parkinson's disease values repr

84 cy (F[1,25] = 52.1 and 53.0, p < 0.0001 for [123I] beta CIT-FP and [18F]FDOPA, respectively).

85 chniques (r = -0.69 and -0.60, p < 0.04 for [123I] beta CIT-FP and [18F]FDOPA, respectively).

86 controls with a mean of V"3=3.5 and 6.7 for [123I]-beta-CIT (Parkinson's disease and controls, respec

87 8 for [123I]beta-CIT-FP and 7.7 +/- 0.7 for [123I]beta-CIT-FE, showing high in vivo selectivity for t

88 tively) and a mean of V"3=1.34 and 3.70 for [123I]-FPCIT (Parkinson's disease and controls, respectiv

89 cific midbrain activity was 9.1 +/- 1.8 for [123I]beta-CIT-FP and 7.7 +/- 0.7 for [123I]beta-CIT-FE,

90 arkinson's disease patients were higher for [123I]-FPCIT than for [123I]-beta-CIT.

91 expressed as a percent reduction per hr for [123I]-FPCIT.

92 The Do dose rates for [123I]IUdR and [125I]IUdR, respectively, are 18.78 and 1.

93 ients were higher for [123I]-FPCIT than for [123I]-beta-CIT.

94 [123I]beta-CIT-FP and a faster washout for [123I]beta-CIT-FE (14.7% +/- 6.9%).

95 ithin 30 min, with little or no washout for [123I]beta-CIT-FP and a faster washout for [123I]beta-CIT

96 ional brain levels of (-)-5-[123I]IBVM ((-)-[123I]5) at 4 h exhibited a linear correlation (r2 = 0.99

97 Intracoronary (IC) 123I-Ang I was administered to 4 heart transplantation r

98 dy was performed to determine differences in 123I image quality at 5 and 24 h for the detection of re

99 The amphetamine-induced decrease in [123I]IBZM binding potential was significantly greater in

100 tive and negative symptoms and increases in [123I]IBZM specific binding.

101 s cholinergic (parasympathetic) innervation, 123I-metaiodobenzylguanidine (MIBG) scintigraphy to meas

102 and, 3-quinuclidinyl-4-[123I]iodobenzilate ([123I]IQNB), binds to muscarinic receptors and has genera

103 ease, NCT00126425; Meta-Iodobenzylguanidine [123I-mIBG] Scintigraphy Imaging in Patients With Heart F

104 phy and the selective 5-HT2A receptor ligand 123I iodinated 4-amino-N-[1-[3-(4-fluorophenoxy)propyl]-

105 s limited to the most commonly used ligand, [123I]beta-CIT, stratification by affection status dramat

106 l, patients with more symptoms showed lower [123I]IBZM specific binding, consistent with competition

107 med by intravenous injection of 191-226 MBq [123I]5-I-A-85380 and image acquisition for 289-367 min.

108 the 1.5-2 h after injection of 185-370 MBq [123I]IACFT.

109 fter oral administration of 56 MBq (1.5 mCi) 123I were concordant in 73% of patients.

110 In protocol 1, 185 MBq (5 mCi) 123I-IPPA were injected intravenously in 19 dogs with 50

111 and 24 hr postinjection of 370 MBq (10 mCi) [123I]beta-CIT.

112 )]- oxo-[1R-(exo-exo)]) and 185 MBq (5 mCi) [123I]iodobenzamide or [123I]iodobenzofuran.

113 aged at 24 hr postinjection 222 MBq (6 mCi) [123I]-beta-CIT and serially from 1-6 hr postinjection 33

114 y from 1-6 hr postinjection 333 MBq (9 mCi) [123I]-FPCIT.

115 d 52% of the control uptake, while the mean [123I]-FPCIT value for Parkinson's disease patients was 3

116 l-4-piperidinyl]-5-iodo-2- methoxybenzamide (123I-5-I-R91150).

117 phenyl)-N-(1-iodoprop-1-en-3-yl)nortropane ([123I]IACFT) for SPECT imaging in an MPTP model of parkin

118 that is well matched to the physical t1/2 of 123I.

119 sured 24 hr after the oral administration of 123I, 3.7-7.4 MBq (0.1-0.2 mCi) with no changes in techn

120 Analysis of 123I transmission images of the nine healthy human contr

121 The dosimetric analysis of 123I-IAZA in 6 healthy volunteers indicated that both di

122 thout corrections for cross-contamination of 123I into the 99mTc window, striatum-to-cerebellum ratio

123 The fractional conversion of 123I-Ang-(1-7) was 0.198+/-0.032 but was reduced to 0.06

124 hod for nonuniform attenuation correction of 123I emission brain images based on transmission imaging

125 h received a nominal 185-MBq (5 mCi) dose of 123I-IAZA administered as a slow (1-3 min) intravenous i

126 on and transmission scans after injection of 123I-beta-CIT.

127 s and emission 123I scans after injection of 123I-beta-CIT.

128 sing a gamma camera after i.p. injections of 123I.

129 amera after i.p. injection of 500 microCi of 123I.

130 versus pretreatment (80%/65%) sensitivity of 123I-MIBG scintigraphy.

131 Values for thyroid uptake of 123I in euthyroid and hyperthyroid patients in Boston ha

132 mors (P-1) which showed no in vivo uptake of 123I, NP-1 tumors accumulated 25-30% of the total 123I a

133 In pulmonary emboli, the absolute uptake of 123I-bitistatin (0.64 +/- 0.17% ID/g) was higher than al

134 g conditions may affect myocardial uptake of 123I-IPPA.

135 ing can be complemented by additional use of 123I-labeled D2/D3 receptor ligand co-injected to assess

136 Striatal accumulation of [123I]IACFT was nearly completely displaceable with unlab

137 rmed after intra-arterial administration of [123I]IUdR in patients with liver metastases and intraves

138 ne-123 fluoropropyl (FP)CIT is an analog of [123I]-beta-CIT and has been shown to achieve peak tracer

139 Analysis of [123I]-FPCIT time-activity curves for specific striatal c

140 ain activity levels, and the application of [123I]IBZM continuous infusion to examine the effects of

141 e healthy male subjects received a bolus of [123I]IBZM followed by a continuous infusion at a bolus (

142 e caused the breakdown of the amide bond of [123I]-31 and rendered this agent obsolete as an in vivo

143 Blood clearance of [123I]IACFT was rapid with a terminal t1/2 of approximate

144 d a similar bolus plus constant infusion of [123I]IBZM.

145 ly 157 +/- 13.7 min after the initiation of [123I]IBZM infusion.

146 ealthy controls obtained after injection of [123I])beta-CIT in part to assess the utility of this tra

147 measures obtained after bolus injection of [123I]beta-CIT 0-7 hr (Day 1) and 18-24 hr (Day 2) after

148 atio measured at 30 min, after injection of [123I]IACFT was significantly higher (p < 0.01) than with

149 5 min) for 3 hr following the injection of [123I]IBZM.

150 4 hr post injection of 360 MBq (9.7 mCi) of [123I]beta-CIT.

151 lia can be acquired with 185 MBq (5 mCi) of [123I]IPT.

152 on of 165 +/- 16 MBq (4.45 +/- 0.42 mCi) of [123I]IPT.

153 The pharmacokinetics of [123I]IUdR locoregionally administered to a human glioma

154 imaging performed at 24 hr postinjection of [123I]beta-CIT permits calculation of reliable and reprod

155 procedures have limited the practicality of [123I]IQNB SPECT imaging.

156 cs, neurobiology, and imaging properties of [123I]IACFT.

157 Radioiodination of [123I]IQNB from our tri-n-butylstannyl precursor is simpl

158 and assumptions about the reversibility of [123I]beta-CIT in striatum.

159 pecificity of scan 89%), the specificity of [123I]FP-CIT SPECT scans was reduced in the FTD group to

160 to radioiodinate the four stereoisomers of [123I]IQNB.

161 ects participated in two kinetic studies of [123I]beta-CIT uptake.

162 ale volunteers was measured with the use of [123I] beta-CIT and single photon emission computed tomog

163 IBI (rest and stress), 123I-/124I-/131I-OIH, 123I/131I-NaI, 125I-iothalamate, 111In-DTPA and 89Sr-SrC

164 o examine the impact of dietary condition on 123I-IPPA metabolic imaging.

165 t 90% of regions that were false negative on 123I-MIBG scintigraphy or [18F]FDA-PET were detected by

166 False-negative results on 123I-MIBG scintigraphy and/or [18F]FDA-PET were not pred

167 renic group, elevated amphetamine effect on [123I]IBZM binding potential was associated with emergenc

168 w of the PET camera were also identified on [123I]MIBG scintigraphic images.

169 visually rating the caudate and putamen on [123I]FP-CIT SPECT scans.

170 participated in one [123I]-beta-CIT and one [123I]-FPCIT SPECT scan separated by 7-21 days.

171 ealthy control subjects participated in one [123I]-beta-CIT and one [123I]-FPCIT SPECT scan separated

172 parison subjects (n=31) participated in one [123I]5-IA-85380 single photon emission computed tomograp

173 Each received one [123I]5-I-A-85380 SPECT scan and an MRI scan.

174 56 rats were injected with GdDTPA-albumin or 123I-GdDTPA-albumin either immediately before reperfusio

175 and 185 MBq (5 mCi) [123I]iodobenzamide or [123I]iodobenzofuran.

176 to assess the performance of beta-methyl-p-[123I]-iodophenyl-pentadecanoic acid (BMIPP) single-photo

177 Whole-body delayed planar [123I]MIBG imaging at 48 hr and SPECT imaging of the ches

178 ll five subjects achieved unchanging plasma [123I]IBZM and striatal brain-activity levels over the 30

179 in addition to its scintigraphic potential ([123I]IUdR and [131I]IUdR), it holds promise for therapy

180 ple radioiodination procedure for preparing [123I]IQNB from a tri-n-butylstannyl precursor in a no-ca

181 primary 99mTc image (130-146 keV), a primary 123I image (152-168 keV) and a secondary 99mTc crosstalk

182 The radioiodines 123I, 124I, 125I and 131I were accommodated as tracers a

183 Specific binding of the D2 radioligand [123I]benzamide ([123I]IBZM) was studied with single phot

184 mography with the nAChR agonist radiotracer [123I]5-IA-85380 ([123I]5-IA), we imaged beta2*-nAChR ava

185 ial of the specific D2 receptor radiotracer [123I] (S)-(-)-3-iodo-2-hydroxy-6-methoxy-N-[(1-ethyl-2-p

186 tomography and the D2 receptor radiotracer [123I]IBZM.

187 and the benzodiazepine receptor radiotracer [123I]iomazenil.

188 (R,S)-[123I]IQNB appears to be the SPECT agent of choice.

189 Nine centres sent 123I-FP-CIT-SPECT data of 344 iRBD patients and 256 cont

190 These findings suggest that serial 123I-IPPA imaging may be useful for assessing myocardial

191 ormal and pathologic studies of simultaneous 123I/99mTc brain SPECT when compensating for all degradi

192 In smokers, [123I]5-IA uptake was significantly higher throughout the

193 yl]tropane (3) with no carrier-added sodium [123I]iodide and hydrogen peroxide in ethanolic HCl.

194 albumin (HSA), 99mTc-MIBI (rest and stress), 123I-/124I-/131I-OIH, 123I/131I-NaI, 125I-iothalamate, 1

195 norepinephrine transporter (NET) substrates [123I]-m-iodobenzylguanidine (MIBG) and [11C]-m-hydroxyep

196 ng selective uptake in the thyroid (99(m)Tc, 123I, and 131I).

197 Of the disintegrins tested, 123I-bitistatin had higher uptake in DVT (0.21 +/- .06%

198 rom striatal tissue 15-20 times faster than [123I]-beta-CIT, and estimates of dopamine transporter lo

199 These results demonstrate that [123I]IACFT is an excellent SPECT ligand for dopamine tra

200 es performed in male rats demonstrated that [123I]1 was selective and specific for SERT.

201 studies performed in rats demonstrated that [123I]ZIET was selective and specific for SERT-rich regio

202 These results indicate that [123I] beta CIT-FP/SPECT can provide quantitative descrip

203 distribution studies in rats indicated that [123I]ZIET enters the brain readily and accumulates in SE

204 Taken together, the data suggests that [123I]16(IMPY) may be useful for imaging A beta aggregate

205 9mTc crosstalk image was subtracted from the 123I image.

206 results showed 1.51% 99mTc crosstalk in the 123I image compared with 12.44% for the uncorrected imag

207 images: results showed 1.3% crosstalk in the 123I image compared with 19.7% for a 10% asymmetric ener

208 ng three experiments with coinjection of the 123I-and 125I-radiolabeled tracer for direct comparison

209 disease biomarkers, brain imaging using the 123I-ioflupane ligand with single-photon emission comput

210 ed from the five control subjects after the [123I]-FPCIT injection for analysis of radiometabolites.

211 16 patients the mean percent decline in the [123I]beta-CIT uptake was significantly greater with levo

212 The sensitivity for each of the [123I]MIBG imaging methods was calculated on a study-by-s

213 w dopamine transporter (DaT) uptake through [123I]FP-CIT-SPECT.

214 ine blood levels were negatively related to [123I]IBZM specific binding.

215 es reductions in striatal uptake similar to [123I]-beta-CIT.

216 NP-1 tumors accumulated 25-30% of the total 123I administered with a biological half-life of 45 h.

217 Final transmural 123I-IPPA LAD/LCX activity ratio (0.99 +/- 0.05) was sig

218 rbomethoxy-3beta-(4-123I-iodophenyl)tropane (123I-beta-CIT); nine healthy human control subjects who

219 -carbomethoxy-3beta-(4-iodophenyl) tropane ([123I]beta-CIT) for measurement of central SERT availabil

220 arboxymethoxy-3-beta-(4-iodophenyl)tropane ([123I]beta-CIT) uptake.

221 arboxymethoxy-3 beta-(4-iodophenyl)tropane ([123I]beta-CIT), were used to determine DA transporter de

222 3 women; aged 19-74 yr) participated in two [123I]beta-CIT SPECT scans separated by 7-14 days.

223 ealthy control subjects participated in two [123I]beta-CIT SPECT scans separated by 7-21 days.

224 on's disease, the Parkinson Study Group used 123I-beta-CIT SPECT.

225 The authors used [123I]5-I-A-85380 single photon emission computed tomogra

226 measuring dopamine transporter levels using 123I-ioflupane single-photon emission computed tomograph

227 e last 16 yr, thyroid RIU measurements using 123I were obtained in 671 euthyroid patients and 274 hyp

228 Using [123I]5-I-A-85380 single photon emission computed tomogra

229 n in the thalamus and temporal cortex using [123I]epidepride SPECT.

230 nts with bladder carcinoma, initially using [123I]IUdR and currently using both [123I]IUdR and [125I]

231 ity of quantifying alpha4beta2 nAChRs using [123I]5-I-A-85380 and support the use of V(T)' as an appr

232 rters and supports the feasibility of using [123I]beta-CIT in serial evaluation of human neuropsychia

233 jects and supports the feasibility of using [123I]beta-CIT in the evaluation of disease progression i

234 e-photon emission computed tomography using [123I]iodobenzovesamicol (IBVM), an in vivo marker of the

235 eparation of *IUdR by demercuration whereby [123I/125I/131I]IUdR is synthesized virtually instantaneo

236 Monkeys were assessed with 123I-PE2I single-photon emission computerized tomography

237 under fasting and nonfasting conditions with 123I-IPPA.

238 Patients were injected with 123I-IPPA (4-5 mCi) at rest with imaging performed at 4

239 mpounds could be used as SPECT (labeled with 123I) or PET (labeled with 18F) radiotracers to image th

240 Blood flow was measured with 123I- or 125I-N-isopropyl-p-iodoamphetamine.

241 Images of DVT obtained with 123I-bitistatin were focally positive within 1 hr and im

242 risk area), viability was overestimated with 123I-IPPA, because uptake averaged 64% of normal in the

243 tivity ratios, as is commonly performed with 123I-beta-CIT, these outcome measures showed only small

244 After radiolabeling with 123I, disintegrins were tested for their ability to imag

245 diagnoses, such as Parkinson's disease with (123I)beta-CIT single photon emission computed tomography

246 eceptor (DD2lR) availability, assessed with [123I]IBZM SPECT, was reduced in the obesity group and st

247 t study was to compare [123I]-beta-CIT with [123I]-FPCIT in a within-subject design.

248 of beta2*-nAChR binding was conducted with [123I]5-I-A-85380 on prefrontal cortex samples from 14 de

249 These data suggest that SPECT imaging with [123I]-FPCIT visually demonstrates reductions in striatal

250 re is increasing evidence that imaging with [123I]FP-CIT SPECT is helpful in differentiating dementia

251 ts of SPECT and delayed planar imaging with [123I]MIBG in neuroblastoma have not yet been fully estab

252 Four healthy volunteers were injected with [123I]-beta-CIT-FP and another four were injected with [1

253 -CIT-FP and another four were injected with [123I]beta-CIT-FE.

254 ient with a cystic glioma was injected with [123I]IUdR.

255 residual nicotine would not interfere with [123I]5-IA binding to the beta2*-nAChR as approximately 7

256 d decline in striatal uptake was noted with [123I] beta CIT-FP (r = -0.56, p < 0.04) but not with [18

257 inetics, and the good results obtained with [123I]ZIET in rats support the candidacy of [11C]ZIET for

258 sympathetic innervation and perfusion with [123I]metaiodobenzylguanidine (MIBG) and 201Tl, respectiv

259 fication of extrastriatal D2 receptors with [123I]epidepride.

260 emission computed tomography scanning with [123I]2beta-carbomethoxy-3beta-(4-iodophenyl) tropane ([1

261 seven patients underwent scintigraphy with [123I]meta-iodobenzylguanidine (MIBG), and two patients w